Overview

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant

Status:
Completed
Trial end date:
2016-08-29
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals